Anavex Life Sciences Corp. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-11-12$6.90 RISE2026-03-25$2.74 PEAK2026-04-20$3.65 159d | -60.3% 133d | Missed | Missed | — | — | +33.2% 26d | Missed |
DROP2025-10-03$9.96 RISE2026-02-05$3.81 PEAK2026-03-04$5.00 152d | -61.7% 125d | Missed | Missed | — | — | +31.2% 27d | Missed |
DROP2025-09-09$10.26 RISE2025-12-31$3.56 PEAK2026-01-21$5.30 134d | -65.3% 113d | Missed | Missed | — | — | +48.9% 21d | Missed |
DROP2025-07-23$13.41 RISE2025-11-24$3.08 PEAK2026-01-21$5.30 182d | -77.0% 124d | Missed | Missed | — | — | +72.1% 58d | Missed |
DROP2025-07-23$13.41 RISE2025-09-24$8.44 PEAK2025-10-03$9.96 72d | -37.1% 63d | Missed | Missed | — | — | +18.0% 9d | Missed |
DROP2025-01-15$11.33 RISE2025-05-27$7.37 PEAK2025-07-23$13.41 189d | -35.0% 132d | Missed | Missed | — | — | +82.0% 57d | Missed |
DROP2025-01-07$13.46 RISE2025-04-08$7.60 PEAK2025-07-03$10.79 177d | -43.5% 91d | Missed | Missed | — | — | +42.0% 86d | Missed |
DROP2025-01-07$13.46 RISE2025-02-27$7.85 PEAK2025-03-20$9.93 72d | -41.7% 51d | Missed | Missed | — | — | +26.5% 21d | Missed |
DROP2024-07-29$7.04 RISE2024-10-10$5.11 PEAK2025-01-07$13.46 162d | -27.4% 73d | Missed | Missed | — | — | +163.4% 89d | Missed |
DROP2024-07-29$7.04 RISE2024-09-10$5.01 PEAK2024-11-29$9.46 123d | -28.9% 43d | Missed | Missed | — | — | +89.0% 80d | Missed |
DROP2024-02-01$6.15 RISE2024-06-11$3.70 PEAK2024-07-29$7.04 179d | -39.8% 131d | Missed | Missed | — | — | +90.3% 48d | Missed |
DROP2023-12-19$9.95 RISE2024-04-25$3.39 PEAK2024-07-23$6.58 217d | -65.9% 128d | Missed | Missed | — | — | +94.1% 89d | Missed |
DROP2023-08-09$9.37 RISE2023-10-23$5.04 PEAK2023-12-19$9.95 132d | -46.2% 75d | Missed | Missed | — | — | +97.4% 57d | Missed |
DROP2023-03-17$9.51 RISE2023-07-27$7.66 PEAK2023-08-09$9.37 145d | -19.5% 132d | Missed | Missed | — | — | +22.3% 13d | Missed |
DROP2022-12-02$12.05 RISE2023-04-12$7.66 PEAK2023-05-17$9.50 166d | -36.4% 131d | Missed | Missed | — | — | +24.0% 35d | Missed |
1–15 / 28 1 / 2 | |||||||
The market is up 1.8% over the last week and has climbed 28% over the past year, with earnings forecast to grow by 17% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when built on solid financials. We've selected three examples of penny stocks that combine balance sheet strength with potential for outsized gains, giving investors a chance to discover hidden value in quality...
The United States market has shown robust performance, rising 1.3% over the last week and 28% over the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential to capitalize on these favorable conditions.
Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it
Anavex appointed former clinical development executive Terrie Kellmeyer as interim CEO following the departure of longtime chief executive Christopher Missling, while also signaling a delay in its quarterly SEC filing. Key Investor TakeawaysAnavex Life Sciences Corp.
Anavex appointed former clinical development executive Terrie Kellmeyer as interim CEO following the departure of longtime chief executive Christopher Missling, while also signaling a delay in its quarterly SEC filing. Key Investor TakeawaysAnavex Life Sciences Corp.
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that its Board of Directors has appointed the Company’s former Senior Vice President of C
AMD downgraded, Airbnb upgraded: Wall Street's top analyst calls
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth expectations, identifying high growth tech stocks that align with these trends can be crucial for investors seeking opportunities in a dynamic sector.
In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth expectations, identifying high growth tech stocks that align with these trends can be crucial for investors seeking opportunities in a dynamic sector.
Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the 10 most shorted penny stocks to buy. More than 500% upside potential as of the April 23 close supports a highly bullish stance on the stock. Recent developments on the ongoing clinical trials also back the argument. On March 23, Anavex Life Sciences Corp. (NASDAQ:AVXL) released […]
Anavex Life Sciences Corp. (NASDAQ:AVXL) is one of the 10 most shorted penny stocks to buy. More than 500% upside potential as of the April 23 close supports a highly bullish stance on the stock. Recent developments on the ongoing clinical trials also back the argument. On March 23, Anavex Life Sciences Corp. (NASDAQ:AVXL) released […]
Airbnb upgraded, Zscaler downgraded: Wall Street's top analyst calls
A Cochrane review finds anti-amyloid Alzheimerâs drugs offer marginal benefits amid high costs/risks. Read the full analysis here.
NEW YORK - Anavex Life Sciences Corp. , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia,...
Anavex Life Sciences (NASDAQ:AVXL) is prioritizing upcoming pivotal studies and continued regulatory engagement as it seeks potential pathways to market authorization for its oral central nervous system (CNS) drug candidate blarcamesine, company executives said during a Needham conference session ho
Anavex Life Sciences (NASDAQ:AVXL) is prioritizing upcoming pivotal studies and continued regulatory engagement as it seeks potential pathways to market authorization for its oral central nervous system (CNS) drug candidate blarcamesine, company executives said during a Needham conference session ho
Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental and neurodegenerative conditions aligns with blarcamesine’s mechanism of action These findings support Anavex’s intent to advance blarcamesine into pivotal clinical studies to further evaluate its potential in addressing unexpectedly common CNS disease mechanisms NEW YORK, April 14, 2026 (GLO
Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD) and Alzheimer's disease (AD), including shared disruptions in autophagy.Epidemiological data show that autistic adults
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 25th Annual Needham Virtual Healthcare Conference, April 13
Over the last 7 days, the market has remained flat, but it is up 16% over the past year with earnings forecast to grow by 15% annually. In light of these conditions, identifying stocks with strong financials and a clear growth trajectory can be beneficial. While "penny stocks" might seem like an outdated term, they still represent smaller or less-established companies that could offer significant value.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AVXL | -8.73% | -33.11% | -14.89% | -59.76% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.70% | -27.40% | -11.44% | -72.45% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 4.51M | $13.85M | 0.00% | Added+2.9% | 2026-03-31 |
| TwoSigma | quant | 3.25M | $9.97M | 0.01% | Added+96.4% | 2026-03-31 |
| RenTech | quant | 276.8K | $849.78K | 0.00% | Added+988.8% | 2026-03-31 |
| Wellington | fundamental | 219.1K | $672.61K | 0.00% | Trimmed-19.5% | 2026-03-31 |
| DEShaw | quant | 44.9K | $137.71K | 0.00% | New | 2026-03-31 |
| FidelityFMR | fundamental | 8.5K | $26.08K | 0.00% | Trimmed-41.1% | 2026-03-31 |
| TRowePrice | fundamental | 63.2K | $195 | 0.00% | Added+36.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-06-01upcoming | -0.07 | — | — |
| 2026-02-09 | -0.11 | -0.06 | +45.45% |
| 2025-11-25 | -0.15 | -0.11 | +26.67% |
| 2025-08-12 | -0.14 | -0.16 | -10.34% |
| 2025-05-13 | -0.15 | -0.13 | +13.33% |
| 2025-02-12 | -0.17 | -0.14 | +17.65% |
| 2024-12-23 | -0.17 | -0.14 | +17.65% |
| 2024-08-06 | -0.18 | -0.14 | +22.22% |
| 2024-05-09 | -0.13 | -0.13 | — |
| 2024-02-07 | -0.15 | -0.11 | +26.67% |
| 2023-11-27 | -0.15 | -0.12 | +20.00% |
| 2023-08-08 | -0.17 | -0.14 | +17.65% |
| 2023-05-09 | -0.18 | -0.17 | +5.56% |
| 2023-02-07 | -0.20 | -0.17 | +15.00% |
| 2022-11-28 | -0.16 | -0.18 | -9.09% |
| 2022-08-09 | -0.16 | -0.16 | +2.04% |